Nonomura K, Shinohara N, Shinno Y, Seki T, Koyanagi T, Nagamori S, Fujieda J, Togashi M, Ohashi N, Abe N, Toyota K, Maru A, Gotoh T, Sakakibara N, Sakashita S, Kosugi M, Adachi Y
Department of Urology, Hokkaido University School of Medicine.
Hinyokika Kiyo. 1996 Sep;42(9):699-704.
A prospective randomized study on the administration of recombinant granulocyte colony stimulating factor (rG-CSF) was conducted on 15 patients with testicular germ cell tumors. The clinical stagings of all patients except one were minimal to moderate extent according to the Indiana University staging system. Combination chemotherapy using bleomycin, etoposide and cisplatinum (BEP) was performed as the initial treatment on the eligible patients. rG-CSF was administered by two different methods; 1) routine administration on the 6th day after BEP chemotherapy (group A), and 2) the same method, but after granulocytopenia of 1,500/mm3 had developed (group B). The administration of rG-CSF in group A significantly reduced the severity of leucocytopenia and also the incidence of stomatitis compared with group B. Although rG-CSF produced no significant side effects, the thrombocytopenia was prominent in the group A patients (not significant). BEP chemotherapy itself is an easily-tolerable and well established method for treating young adult patients. The method used in group B seems to be suitable in situations where thrombocytopenia and cost effectiveness.
对15例睾丸生殖细胞肿瘤患者进行了一项关于重组粒细胞集落刺激因子（rG-CSF）给药的前瞻性随机研究。根据印第安纳大学分期系统，除1例患者外，所有患者的临床分期均为轻度至中度。对符合条件的患者进行以博来霉素、依托泊苷和顺铂（BEP）为基础的联合化疗作为初始治疗。rG-CSF通过两种不同方法给药：1）在BEP化疗后第6天常规给药（A组），以及2）同样的方法，但在粒细胞减少至1500/mm³后给药（B组）。与B组相比，A组中rG-CSF的给药显著降低了白细胞减少的严重程度以及口腔炎的发生率。尽管rG-CSF未产生显著副作用，但A组患者的血小板减少较为突出（无统计学意义）。BEP化疗本身是一种易于耐受且成熟的治疗年轻成年患者的方法。B组所采用的方法似乎适用于存在血小板减少和成本效益的情况。
